CRBU vs. ALLO

Last updated Apr 2, 2026

Compare and contrast key facts about Caribou Biosciences, Inc. (CRBU) and Allogene Therapeutics, Inc. (ALLO).

Performance

CRBU vs. ALLO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Caribou Biosciences, Inc. (CRBU) and Allogene Therapeutics, Inc. (ALLO). The values are adjusted to include any dividend payments, if applicable.

CRBU vs. ALLO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
CRBU Caribou Biosciences, Inc.	25.16%	0.00%	-72.25%	-8.76%	-58.38%	-7.54%
ALLO Allogene Therapeutics, Inc.	86.86%	-35.68%	-33.64%	-48.97%	-57.84%	-32.34%

Fundamentals

Market Cap CRBU : $188.13M ALLO : $564.79M
EPS CRBU : -$1.58 ALLO : -$0.87
PB Ratio CRBU : 1.54 ALLO : 1.93
Total Revenue (TTM) CRBU : $11.16M ALLO : $0.00
Gross Profit (TTM) CRBU : $9.85M ALLO : $0.00
EBITDA (TTM) CRBU : -$130.70M ALLO : -$209.32M

Returns By Period

In the year-to-date period, CRBU achieves a 25.16% return, which is significantly lower than ALLO's 86.86% return.

CRBU

• 1D: 4.74%
• 1M: 8.15%
• YTD: 25.16%
• 6M: -11.95%
• 1Y: 136.59%
• 3Y*: -27.90%
• 5Y*: —
• 10Y*: —

ALLO

• 1D: 4.92%
• 1M: -3.40%
• YTD: 86.86%
• 6M: 106.45%
• 1Y: 86.86%
• 3Y*: -19.68%
• 5Y*: -40.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CRBU vs. ALLO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRBU

CRBU Risk / Return Rank: 79
CRBU Sharpe Ratio Rank: 84
CRBU Sortino Ratio Rank: 82
CRBU Omega Ratio Rank: 75
CRBU Calmar Ratio Rank: 79
CRBU Martin Ratio Rank: 74

ALLO

ALLO Risk / Return Rank: 71
ALLO Sharpe Ratio Rank: 73
ALLO Sortino Ratio Rank: 73
ALLO Omega Ratio Rank: 70
ALLO Calmar Ratio Rank: 73
ALLO Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRBU vs. ALLO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Caribou Biosciences, Inc. (CRBU) and Allogene Therapeutics, Inc. (ALLO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRBU	ALLO	Difference
Sharpe ratio Return per unit of total volatility	1.53	1.00	+0.53
Sortino ratio Return per unit of downside risk	2.30	1.81	+0.49
Omega ratio Gain probability vs. loss probability	1.26	1.22	+0.03
Calmar ratio Return relative to maximum drawdown	2.31	1.71	+0.60
Martin ratio Return relative to average drawdown	4.40	3.24	+1.15
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRBU vs. ALLO - Sharpe Ratio Comparison

The current CRBU Sharpe Ratio is 1.53, which is higher than the ALLO Sharpe Ratio of 1.00. The chart below compares the historical Sharpe Ratios of CRBU and ALLO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CRBU	ALLO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.53	1.00	+0.53
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.48	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.41	-0.34	-0.07

Correlation

The correlation between CRBU and ALLO is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

CRBU vs. ALLO - Dividend Comparison

Neither CRBU nor ALLO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CRBU vs. ALLO - Drawdown Comparison

The maximum CRBU drawdown since its inception was -97.58%, roughly equal to the maximum ALLO drawdown of -98.24%. Use the drawdown chart below to compare losses from any high point for CRBU and ALLO.

Drawdown Indicators

	CRBU	ALLO	Difference
Max Drawdown Largest peak-to-trough decline	-97.58%	-98.24%	+0.66%
Max Drawdown (1Y) Largest decline over 1 year	-51.06%	-43.95%	-7.11%
Max Drawdown (5Y) Largest decline over 5 years	—	-97.34%	—
Current Drawdown Current decline from peak	-93.43%	-95.26%	+1.83%
Average Drawdown Average peak-to-trough decline	-78.77%	-65.15%	-13.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.83%	23.23%	+3.60%

Volatility

CRBU vs. ALLO - Volatility Comparison

The current volatility for Caribou Biosciences, Inc. (CRBU) is 21.37%, while Allogene Therapeutics, Inc. (ALLO) has a volatility of 32.12%. This indicates that CRBU experiences smaller price fluctuations and is considered to be less risky than ALLO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRBU	ALLO	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.37%	32.12%	-10.75%
Volatility (6M) Calculated over the trailing 6-month period	54.67%	66.75%	-12.08%
Volatility (1Y) Calculated over the trailing 1-year period	90.21%	87.91%	+2.30%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	87.51%	84.41%	+3.10%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	87.51%	77.62%	+9.89%

Financials